Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Exenatide Shows Benefits Over Byetta | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Exenatide Shows Benefits Over Byetta

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amylin Pharmaceuticals, Lilly and Alkermes announced results from a 30-week study comparing the efficacy of exenatide once weekly (a long-acting release formulation of exenatide) to Byetta (the injectable version of exenatide), in type 2 diabetes. Patients treated with exenatide once weekly, an investigational therapy, showed statistically significant improvements in A1c and fasting plasma glucose from baseline compared with Byetta. Patients in both treatment groups also reported significant weight loss (average of 8 pounds) and 77% of patients treated with exenatide achieved an A1c of 7% or less.  
   
Byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione but have not achieved adequate glycemic control.
   
The 30-week study was randomized, open-label study of 295 patients with type 2 diabetes who were treated with exenatide once weekly 2.0 mg or Byetta twice daily subcutaneously. Patients in both groups who completed the randomized portion of the study continued in an open-ended portion of the study to receive exenatide once weekly.
   
Exenatide once weekly uses a technology for long-acting medications developed by Alkermes, which encapsulates active medication into polymer-based microspheres that are injected into the body where they degrade slowly, gradually releasing the drug in a controlled manner to provide continuous therapeutic concentrations.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters